Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04310579 · ClinicalTrials.gov registry record · Phase 1
Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation
A Phase 1 study of Hypercapnia and Ventilatory Depression, sponsored by Food and Drug Administration (FDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT04310579 is a Phase 1 study of Hypercapnia and Ventilatory Depression that has completed, run by Food and Drug Administration (FDA). The registered enrollment target is 55 participants, above the 48-participant average among 5 other Hypercapnia trials with a reported enrollment target (15% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04310579, a Phase 1 study of Hypercapnia and Ventilatory Depression, has completed, sponsored by Food and Drug Administration (FDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Opioids can decrease breathing and co-administration of benzodiazepines with opioids can further decrease breathing. It is unknown whether certain other drugs also decrease breathing when co-administered with opioids. The objective of this study is to determine whether certain drugs combined with an opioid decrease breathing compared to breathing with an opioid alone. In order to assess this, this study will utilize the Read Rebreathing method, where study participants breathe increased levels of oxygen and carbon dioxide. The increased levels of carbon dioxide cause the study participants to increase breathing. This increased breathing response can be decreased by opioids and benzodiazepines, and potentially other drugs. Using this procedure, low doses of opioids or benzodiazepines can be administered that have minimal-to-no effects on breathing when study participants are going about normal activities breathing room air, however breathing increases less than expected as carbon dioxide levels are increased. This study will also obtain quantitative pupillometry measurements before and after each rebreathing assessment to allow for comparisons of pupillary changes to ventilatory changes when subjects receive different drugs and drug combinations. This study includes three parts: A Lead-In Reproducibility Phase and two main parts (Part 1 and Part 2). The Lead-In Reproducibility Phase will measure the variability between study participants and between repeated uses of the method in the same study participant within a day and between days. Part 1 will study an opioid alone, benzodiazepine alone, and their combination to show the methodology will detect changes in breathing at low doses of the drugs that are known to affect breathing. Part 2 will assess whether two drugs, selected due to their effects on breathing in a nonclinical model, decrease the breathing response when combined with an opioid compared to when an opioid is administered alone.
Conditions Studied
Interventions
- DRUG Oxycodone and Midazolam
- DRUG Oxycodone, Paroxetine, and Quetiapine
Study Locations (1)
Wisconsin
- Spaulding Clinical Research - West Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2021-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04310579
The ClinicalTrials.gov registry entry for NCT04310579 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 48-participant average among 5 other Hypercapnia trials with a reported enrollment target (15% higher). The listed sponsor is Food and Drug Administration (FDA), which has 23 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypercapnia appearing as the primary indexed condition, and to 2 interventions - of which Oxycodone and Midazolam is the first listed.
NCT04310579 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04310579 about?
NCT04310579 is a clinical study titled "Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation". Opioids can decrease breathing and co-administration of benzodiazepines with opioids can further decrease breathing. It is unknown whether certain other drugs also decrease breathing when co-administered with opioids. The objective of this study is to determine whether certain drugs combined with an...
What is the current status of trial NCT04310579?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2020-06-15. Estimated completion is 2021-05-25.
What conditions does trial NCT04310579 study?
This clinical trial studies the following conditions: Hypercapnia, Ventilatory Depression.
What interventions are being tested in trial NCT04310579?
The interventions under investigation include: Oxycodone and Midazolam (DRUG), Oxycodone, Paroxetine, and Quetiapine (DRUG).
Who is sponsoring clinical trial NCT04310579?
This trial is sponsored by Food and Drug Administration (FDA), which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04310579 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercapnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oxygen Toxicity: Mechanisms in Humans
RECRUITING · NA
-
Effect of Hypercapnia Treatment on Respiratory Recovery After Spinal Cord Injury
RECRUITING · NA
-
"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"
COMPLETED · NA
-
Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Cannulae Designs
COMPLETED · NA
-
Study of Brain Blood Flow During Induced Hypercapnia (Excess Blood Carbon Dioxide)
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.